Tech Company Financing Transactions
Aires Pharmaceuticals Funding Round
On 11/12/2010, Aires Pharmaceuticals raised $20 million in Series B financing from MPM Capital and ProQuest Investments.
Transaction Overview
Company Name
Announced On
11/12/2010
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series B
Investors
MPM Capital (Lead Investor) (William Greene)
Proceeds Purpose
Additionally, Aires further bolstered its cash reserves by entering into an agreement with Novartis International Pharmaceutical Limited whereby Novartis has been granted an exclusive option to acquire Aires following the successful completion of a Phase 2 clinical study of Aironite� to treat pulmonary arterial hypertension.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
4365 Executive Dr. 1500
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
As a first product opportunity, the Company is developing an inhaled drug that has been demonstrated in animal models to treat both adult and pediatric pulmonary hypertension. As a second product opportunity, Aires is also pursuing indications associated with the treatment of bacterial pulmonary infections.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Wendy Johnson
Chief Medical Officer
Edwin Parsley
VP - Finance
Julie Crawford
VP - Product Management
Hiroko Masamune
Browse more venture capital transactions:
Prev: 11/12/2010: Clearleap venture capital transaction
Next: 11/12/2010: Axis Semiconductor venture capital transaction
Share this article
News on VC Transactions
We do our best to record every notable VC transaction. VC investment data records reported here come from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs